Hirata, Koichi
Sakai, Fumihiko
Takeshima, Takao
Imai, Noboru
Matsumori, Yasuhiko
Yoshida, Ryuji
Numachi, Yotaro
Peng, Cheng
Mikol, Daniel D.
Cheng, Sunfa
Funding for this research was provided by:
amgen k.k
Article History
Received: 22 June 2021
Accepted: 3 August 2021
First Online: 18 September 2021
Change Date: 14 October 2021
Change Type: Update
Change Details: The links to the additional files were broken. The article has been updated to rectify this.
Declarations
:
: The study protocol was approved by the ethics committee or institutional review board at each clinical site, and all patients provided a signed informed consent before the start of any study-related procedures. The study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Guideline and conforms to the provisions of the Declaration of Helsinki. All authors were given access to the study data.
: Not applicable.
: KH: grants from the Ministry of Health, Labor and Welfare, grants from The Japan Agency for Medical Research and Development, and nonfinancial support from Alexion Pharmaceuticals, Inc. FS: membership of advisory boards for Amgen, Eli Lilly and Company, and Teva Pharmaceuticals. SC, CP, RY, YN, DDM: employees and stockholders of Amgen. NI, TT, YM: these authors declare that they have no competing interests.